PDCD1 and melanoma: Recently, new treatment approaches such as antibodies targeting the immune checkpoints T-lymphocyte-associated protein 4 (CTLA-4) or the programmed cell death protein 1 (PD-1) either used alone or as combined immunotherapy remarkably improved prognosis of advanced melanoma.